(Q37059750)

18 August 2017

1 reference

title

The role of TRAIL death receptors in the treatment of hematological malignancies (English)

1 reference

18 August 2017

Elizabeth S Henson

1

1 reference

18 August 2017

James B Johnston

series ordinal

2

1 reference

18 August 2017

Spencer B Gibson

series ordinal

3

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

49

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

27-35

1 reference

Death receptors: signaling and modulation

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

On the TRAIL of a new therapy for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Targeting death receptors in cancer with Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Monoclonal antibodies against TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Apoptosis control by death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Evidence that the human death receptor 4 is regulated by activator protein 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

TRAIL signalling: decisions between life and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

The triterpenoid CDDO induces apoptosis in refractory CLL B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

TRAIL and its receptors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

The clinical trail of TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713655

10.1080/10428190701713655

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference